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In contrast to cutaneous melanoma, there is no evidence that BRAF mutations are involved in the activation of the mitogen-activated
protein kinase (MAPK) pathway in uveal melanoma, although there is increasing evidence that this pathway is activated frequently in
the latter tumours. In this study, we performed mutation analysis of the RAS and BRAF genes in a panel of 11 uveal melanoma cell lines
and 19 primary uveal melanoma tumours. In addition, Western blot and immunohistochemical analyses were performed on
downstream members of the MAPK pathway in order to assess the contribution of each of these components. No mutations were
found in any of the three RAS gene family members and only one cell line carried a BRAF mutation (V599E). Despite this, mitogen-
activated protein kinase/extracellular signal-regulated kinase kinase (MEK), ERK and ELK were constitutively activated in all samples.
These data suggest that activation of the MAPK pathway is commonly involved in the development of uveal melanoma, but occurs
through a mechanism different to that of cutaneous melanoma.
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Uveal melanoma is the most common primary intraocular tumour
in adults, with an annual incidence of 6–8 new cases per million
among Caucasian populations. Up to half of all patients die from
metastatic disease (Diener-West et al, 1992). In spite of several
known prognostic markers (pathologic and genetic), such as
tumour cell type, diameter, localisation and cytogenetic abnorm-
alities, little is known about specific genes associated with
predisposition and progression in uveal melanoma (Mooy and
de Jong, 1996; Sisley et al, 1997). Notable exceptions are
hypermethylation of CDKN2A, which is more common in tumours
from patients who develop metastatic disease (van der Velden
et al, 2001), and germline BRCA2 gene mutations, which occur in
3% of patients younger than 50 years of age (Scott et al, 2002).
Hence, the search for other genes and molecular pathways
involved in uveal melanoma development is of great significance.
In contrast to uveal melanoma, the influence of specific pathways
in cutaneous melanoma, which shares the same embryonic origin,
is better defined. For instance, the tumour suppressor gene PTEN,
encoding a dual-specific phosphatase and a member of the PI3-
AKT pathway, plays a major role in the pathogenesis of cutaneous
melanoma (Guldberg et al, 1997; Stahl et al, 2003), whereas no
mutations in this gene have been found in uveal melanoma (Naus
et al, 2000).
Recently, the RAS-RAF-MEK-ERK or mitogen-activated protein
kinase (MAPK) pathway has been found to play an important role
in melanocytic neoplasia (Cohen et al, 2002; Satyamoorthy et al,
2003). Activation of this pathway in cutaneous melanocytes has
been shown to occur by a variety of mechanisms, including
autocrine growth factor stimulation and mutation of the RAS or
BRAF genes. Of three RAS genes found to be activated by
mutation in human tumours, NRAS (neuroblastoma RAS viral (v-
ras) oncogene homologue) is most commonly mutated in
cutaneous melanomas (van Elsas et al, 1996). In the active GTP-
bound state, RAS activates a number of downstream signalling
cascades involved in controlling cell growth and behaviour.
Initially, RAS interacts with and activates the serine/threonine
protein kinase BRAF that acts in the MAPK pathway to transduce
regulatory signals from RAS to mitogen-activated protein kinase/
extracellular signal-related kinase kinase (MEK1/2). The signal
transducer MEK1/2 phosphorylates extracellular signal-regulated
kinase (ERK1/2, p44/42), leading to the activation of these kinases,
which in turn activate a variety of transcription factors, including
ELK1, again through phosphorylation. It has emerged that BRAF
(v-raf murine sarcoma viral oncogene homologue B1) is very
frequently activated by mutation in cutaneous melanomas (Brose
et al, 2002; Davies et al, 2002; Alsina et al, 2003; Dong et al, 2003;
Gorden et al, 2003; Kumar et al, 2003a,b; Maldonado et al,
2003; Omholt et al, 2003; Pollock et al, 2003; Rimoldi et al, 2003;
Satyamoorthy et al, 2003; Weber et al, 2003; Cohen et al, 2004;
Reifenberger et al, 2004; Shinozaki et al, 2004; Tsao et al, 2004).
The frequency of BRAF mutations varies from 8 to 83% depending
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son the anatomic site of the lesion and its histogenic subtype.
Notably, the frequency of BRAF mutations is also high in benign
melanocytic naevi (Dong et al, 2003; Pollock et al, 2003; Uribe
et al, 2003; Yazdi et al, 2003), indicating that constitutive
activation of the MAPK pathway is an early event in melanoma-
genesis. All BRAF mutations in cutaneous pigmented neoplasms
occur within the kinase domain. The most frequently found
mutation in BRAF (V599E) consists of a 1796T-A transversion in
exon 15 (Davies et al, 2002). Various other mutations have been
described in this exon in melanocytic tumours (V599D (Brose
et al, 2002; Davies et al, 2002; Pollock et al, 2003); V599K (Pollock
et al, 2003, Uribe et al, 2003); V599R (Pollock et al, 2003); K600E
(Brose et al, 2002, Satyamoorthy et al, 2003)). All other mutations
have been described in exon 11. The latter consist of a 1352A-C
transversion (K438Q) (Brose et al, 2002), a 1402G-A transition
(G468R) and a 1402/1403GG-TC tandem transversion (Gorden
et al, 2003), a 1394G-A transition (G465E) and a 1394G-C
transversion (G465A) (Davies et al, 2002). Furthermore, it is not
surprising that since they activate the same pathway, mutations in
NRAS and BRAF are almost mutually exclusive (Brose et al, 2002;
Davies et al, 2002; Alsina et al, 2003; Dong et al, 2003;
Gorden et al, 2003; Kumar et al, 2003a,b; Omholt et al, 2003;
Pollock et al, 2003; Satyamoorthy et al, 2003; Reifenberger et al,
2004; Tsao et al, 2004).
Since cutaneous and uveal melanoma both arise from neural
crest-derived melanocytes, we sought to assess whether the
MAPK pathway was similarly activated in melanoma of the uvea.
We thus screened for activating mutations in the NRAS, HRAS,
KRAS and BRAF genes in uveal melanoma cell lines and primary
uveal melanomas. Sequence analysis was performed on exons
11–15 of BRAF, and exons 1 and 2 of the three RAS family
members, which cover the positions of all known mutations of
these genes in all types of cancer. In addition, we performed
immunohistochemistry and Western blot analysis with MEK,
ERK and ELK antibodies both on cell lines and/or primary
tumours to assess the level of expression and degree of
activation of these proteins in order to provide insight into
the involvement of this pathway in the development of uveal
melanoma.
MATERIALS AND METHODS
Cell lines and primary uveal melanoma specimens
In total, 11 uveal melanoma cell lines, derived from primary uveal
melanomas (Mel202, Mel 285, Mel 270, Mel 290, Ocm 1, Ocm 3,
92.1, 92.2) or uveal melanoma metastases (Omm 1 Omm 1.3 and
Omm 1.5), were analysed. Mel 202, Mel 285, Mel 270, Mel 290 and
the two cell lines derived from metastases (Omm 1.3 and Omm 1.5)
were kindly provided by Dr BR Ksander (Schepens Eye Institute,
Boston, MA, USA). Omm 1, obtained from a subcutaneous
metastasis, was established by Dr Luyten (Luyten et al, 1996).
The cell lines Ocm 1 and Ocm 3 were provided by Dr Kan-Mitchell
(Kan-Mitchell et al, 1989) and cell lines 92.1 and 92.2, derived from
the same primary tumour were established in our own laboratory
(de Waard-Siebinga et al, 1995). The melanoma cell lines were
cultured in RPMI 1640 (Gibco, Paisley, Scotland) medium,
supplemented with 3mML -glutamine (Gibco), 2% penicillin/
streptomycin and 10% FBS (Hyclone, Logan, UT, USA). All cell
cultures were incubated at 371C in a humidified 5% CO2
atmosphere. In addition, we analysed 19 primary fresh frozen
uveal melanomas. Of the primary tumours, eight were located in
the choroid and 11 in both the choroid and ciliary body. Four of
these samples showed a spindle cell type, one an epithelioid cell
type and 14 had a mixed population of cells. All samples were
derived from tumours with a diameter greater than 12ml and a
prominence greater than 6ml. The research protocol followed the
tenets of the Declaration of Helsinki (World Medical Association
Declaration of Helsinki 1964; ethical principles for medical
research involving human subjects).
Sequencing
DNA was extracted from each cell line using an adaptation of the
salting-out method (Miller et al, 1988). Primers used to amplify
parts of the BRAF and RAS genes are given in Table 1.
Reactions for BRAF contained 200 ng of DNA, QIAGEN (Hilden,
Germany) PCR buffer (10  concentrated, containing Tris-Cl, KCl,
(NH4)2SO4,1 5 m M MgCl2; pH 8.7), Q solution (PCR enhancer),
Table 1 PCR primers for BRAF, NRAS, KRAS and HRAS genes
Samples Gene Exon/region Primer name Primer sequence (50430) Product size (bp)
Cell lines BRAF 11 x11F CTCTCAGGCATAAGGTAATGTAC
(DNA) x11R GAGTCCCGACTGCTGTGAAC 360
BRAF 15 x15F CTAAGAGGAAAGATGAAGTACTATG
x15R CTAGTAACTCAGCAGCATCTCAG 328
NRAS 1 X1F CTGGTTTCCAACAGGTTCTTG
X1R TGCTACTCCAATCATCTGGTC 567
NRAS 2 X2F CACACCCCCAGGATTCTTAC
X2R GTTCCAAGTCATTCCCAGTAG 438
HRAS 1 X1F GGCAGGAGACCCTGTAGGA
X1R AGCCCTATCCTGGCTGTGT 232
HRAS 2 X2F AGAGGCTGGCTGTGTGAACT
X2R ACATGCGCAGAGAGAGGACAG 344
KRAS 1 X1F GATTTTCCTAGGCGGCGG
X1R GTCCGCTCCGTACCTCTCTC 199
KRAS 2 X2F GGCCTGCTGAAAATGACTG
X2R TATTGTTGGATCATATTCGTCCAC 120
Tumours BRAF 11–15 F TCAACCACAGGTTTGTCTGC
(cDNA) R GATGACTTCTGGTGCCATCC 696
NRAS F GGGGTCTCCAACATTTTTCC
R TCGCTTAATCTGCTCCCTGT 390
HRAS F CAGGAGACCCTGTAGGAGGA
R TTTACTGTGATCCCATCTGTGC 968
KRAS F AGGCCTGCTGAAAATGACTG
R TTCAATCTGTATTGTCGGATCTC 519
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s20pmolml
 1 of each primer, 2mM of each dNTP and 1.25U of
QIAGEN Taq polymerase. Amplification involved 35 cycles of
denaturation at 941C for 45s, annealing at 561C for 90s, and
extension at 721C for 90s. An initial 12min denaturation step at
941C and a final 3min extension at 721C were also used. For the
RAS genes, DNA was amplified using QIAGEN Taq polymerase as
described above, but PCR involved a ‘touchdown’ thermal cycling
routine of two cycles at each annealing temperature, decreasing by
steps of 21C, followed by 25 cycles at the lowest temperature. Each
cycle consisted of denaturation at 941C for 45s, annealing at 65–
571C for 90s and extension at 721C for 90s. An initial 12min
denaturation at 941C and a final 3min extension at 721C were also
employed.
From 19 fresh frozen uveal melanoma samples, total RNA was
extracted with RNeasy kits as described by the manufacturer
(QIAGEN). RNA was primed with random primers and reverse
transcribed into cDNA in a 20ml reaction volume containing 200U
Superscript II (MMV) reverse transcriptase (Invitrogen, Inc.,
Breda, The Netherlands). PCR primers used for amplifying parts
of the BRAF and RAS genes in the primary tumour samples are
also listed in Table 1. A touchdown PCR procedure for BRAF was
followed as described above and a fixed annealing temperature of
571C with a total of 38 cycles was used for the RAS genes followed
by a final elongation step of 10min.
PCR products of all samples were electrophoresed through 1.5%
TAE/agarose gels stained with ethidium bromide, excised and
purified using a QIAGEN QIAquick Gel Extraction Kit. The RAS
and BRAF PCR products were sequenced using Applied Biosys-
tems (ABI) BigDye version 3 reagents according to the manu-
facturer’s instructions using 3.2pmolml
 1 of primer. Sequencing
products were precipitated using 75% isopropanol and were run
on an ABI 377 automated sequencer (PE Applied Biosystems,
Foster City, CA, USA).
Western blot analysis
Protein lysates from the uveal melanoma cell lines were separated
on 12.5% SDS–PAGE gels and the proteins transferred to Hybond-
polyvinyldifluoride membranes (Amersham biosciences, Buckin-
ghamshire, UK). After blocking with 5% skim milk in PBS-Tween
solution, the membranes were probed overnight at 41C with the
following primary antibodies specific to each antigen: phospho-
MEK1/2 (dilution 1:1000), phospho-ERK1/2 (p44/42) (#9106,
dilution 1:5000), total ERK1/2 (#9102, dilution 1:1000) and
phospho-ELK1 (dilution 1:1000) antibody (all from Cell Signaling
Technology, Hertfordshire, UK). An antibody against actin (Santa
Cruz Biotechnology, California, USA) was used as a loading control.
Membranes were then incubated with horseradish peroxidase-
conjugated IgG anti-mouse, anti-rabbit or anti-goat secondary
antibodies for 1h at room temperature to visualise protein bands.
Immunohistochemistry
Acetone-fixed 10mm sections of 19 fresh frozen uveal melanomas
were washed three times in PBS (pH¼7.2) and were incubated
with anti-ERK1/2 and anti-phospho-ERK 1/2 antibodies (Cell
Signalling Technology, Beverly MA, USA, #9102 and #9106,
respectively), both diluted 1:100 in PBS with 1% BSA and 2%
normal human serum (NHS) at 41C. The sections were washed
three times and incubated with cy3-conjugated AffiniPure goat
anti-rabbit IgG or with cy3-conjugated AffiniPure rabbit anti-
mouse IgG (Jackson ImmunoResearch, West Grove PA, USA #111-
165-003 and #315-165-003) both diluted 1:500, respectively,
during 1h at room temperature. Sections were rinsed with PBS
three times and incubated for 20min with Alexa Fluor 647
Phalloidin (Molecular Probes, Leiden, The Netherlands, #A22287)
at a 1:40 dilution. Sections are washed three times with PBS. A
nuclear staining was preformed by incubating the sections for
5min with 40,6-diamidino-2-phenylindole dilacetate (DAPI, Mole-
cular Probes, Leiden, The Netherlands, #D-3571) 1:500. Sections
were rinsed briefly in PBS and imbedded with Vectashield (Vecta
Shield H1000, Brunschwig, Amsterdam, The Netherlands). For
each specimen, the fluorescence of cy3 was determined in three
different microscope fields (Leica DMRXA microscope, Leica
Microsystems, Rijswijk, The Netherlands). No background fluor-
escence of cy3 was observed. The number of positively stained
tumour cells was estimated for the two antibodies and expressed as
the percentage of the total number of tumour cells in the analysed
section. Percentages were then categorised as either negative o5%
(þ/ ), very weakly positive 5–25% (þ), weakly positive 26–50%
(þþ), moderately positive 51–75% (þþþ) or highly positive
76–100% (þþþþ).
The slides were examined by two observers independently.
Interobserver disagreement did not exceed one category.
RESULTS
Mutation analysis
Of the 11 uveal melanoma cell lines under study, only one cell line
(Ocm 1) carried a BRAF mutation, the common V599E (also
described by Calipel et al and Kilic et al). All primary tumour
specimens were wild type for BRAF. No mutations were found in
the NRAS, HRAS or KRAS genes, in both the cell lines and primary
tissue.
Western blotting
In order to assess the level of expression and the activation (by
phosphorylation) of members of the MAPK pathway downstream
of RAS and BRAF, Western blot analysis was performed on uveal
melanoma cell lines (Table 2A). The expression levels of the
downstream members of RAS and BRAF are presented in Figure 1.
In response to the constitutively activating BRAF mutation in Ocm
1, downstream members of the MAPK pathway show activation
(phosphorylated MEK, ERK and ELK). Levels of expression of the
downstream members were not different in the two cell lines
derived from the same primary tumour (92.1 and 92.2), except for
phosphorylated MEK, indicating that there had been little clonal
divergence between the cell populations during in vitro culturing.
Interestingly, compared to the phosphorylation status of these
members in Ocm 1, most cell lines show activation of MEK, ERK
and ELK; however, these cell lines show this activation in the
absence of mutations in the upstream RAS and BRAF genes. The
levels of total ERK were remarkably similar across all cell lines,
with the exception of two cell lines Mel 285 and Mel 290, which had
significantly higher levels of total ERK than the others. In keeping
with this observation, these two cell lines also have the highest
levels of phosphorylated-ERK. Figure 2 shows that there is no
significant influence of serum on the activity of ERK1/2 in these
cell lines, as reported recently by Calipel et al (2003).
Immunohistochemistry
Immunofluorescence results of total and phospho-ERK1/2 on a
panel of 19 fresh frozen uveal melanoma sections are listed in
Table 2 (B). In seven of the 19 primary tumours, less than 5% of
the tumour cells stained positively for ERK1/2 and nine tumours
for phosphorylated ERK1/2. Despite the lack of mutations in the
RAS and BRAF genes in this set of uveal melanomas, it is
noteworthy that we observed phosphorylated (active) ERK1/2
expression in 10 of 19 tumours. There was no significant
association between ERK1/2 activation and tumour location or
cell type. The scoring system for each antibody cannot be
compared between antibodies since the antibodies recognise
different epitopes and with different affinities; therefore, the
MAPK pathway activation in uveal melanoma
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sstaining intensity on Western or by immunohistochemistry is
relative only to the other samples for the particular antibody used.
DISCUSSION
In the uveal melanoma cell lines and primary uveal melanomas
analysed in our study, only cell line Ocm 1 carried a mutation in
BRAF (V599E), thus confirming the documentation of a mutation
in this cell line by Calipel et al (2003) and Kilic et al (2004).
Similarly, our observation of a complete lack of BRAF mutations in
primary uveal tumours mirrors the findings of several recent
reports (Cohen et al, 2003; Cruz et al, 2003; Edmunds et al, 2003;
Rimoldi et al, 2003; Weber et al, 2003; Kilic et al, 2004). Table 3
contains a summary of published reports on RAS and BRAF
mutations, as well as studies on other members of the MAPK
pathway, in uveal melanomas. Including the results of our study, to
date not a single BRAF mutation has been found in a total of 276
primary or secondary uveal melanoma samples (Table 3). It is
somewhat surprising therefore that three out of three uveal
melanoma cell lines studied by Calipel et al (2003) carried the
V599E mutation in BRAF, especially since only one out of 11 cell
lines in the panel we analysed was found to have this mutation.
Taken together, these data suggest that while a BRAF mutation is
not required for uveal melanoma development in vivo, such
mutations confer a cellular growth advantage and are hence
selected if they occur in cell lines cultured in vitro.
In our study, none of the cell lines or primary tumours carried
mutations in any of the three RAS genes (N, H and K), a finding
consistent with a previous report (Soparker et al, 1993). These
mutation data are in stark contrast to that for cutaneous
melanoma, and would appear to suggest that the MAPK pathway
is unlikely to play a significant role in uveal melanoma
development. However, on the contrary, by Western blot analysis
and immunohistochemistry, we have found substantial evidence
for activation of the MAPK pathway, in the absence of serum, in
the majority of uveal melanoma samples – both cell lines and
primary uveal melanoma specimens. This frequent MAPK pathway
Table 2 Summary of mutation analyses, immunohistochemical and Western blotting data in uveal melanoma cell lines and primary uveal melanomas
(A) Uveal melanoma cell lines
Cell line
BRAF
mutation
analysis
NRAS
mutation
analysis
KRAS
mutation
analysis
HRAS
mutation
analysis
Total ERK
Western
Phospho-ERK
Western
Phospho-MEK
Western
Phospho-ELK
Western
From primaries
Ocm 1 V599E WT WT WT +++ +++ ++++ +++
Mel 285 WT WT WT WT ++++ ++++ ++ ++
Mel 290 WT WT WT WT ++++ ++++ +++ ++
92.1 WT WT WT WT +++ ++ +++ +++
92.2 WT WT WT WT +++ ++ ++ +++
Ocm 3 WT WT WT WT +++ ++ ++++ +++
Mel 202 WT WT WT WT +++ ++ +++ +++
Mel 270 WT WT WT WT +++ ++ +++ ++
From metastases
Omm 1.3 WT WT WT WT +++ + + +++
Omm 1.5 WT WT WT WT +++ + + +++
Omm 1 WT WT WT WT +++ + ++++ +++
(B) Primary uveal melanomas
Tumour sample
ID
BRAF
mutation
analysis
NRAS
mutation
analysis
KRAS
mutation
analysis
HRAS
mutation
analysis
Total ERK1/2
IHC
Phospho ERK1/2
IHC
1 W TW TW TW T + + + + + +
2 WT WT WT WT +++ +++
3 W TW TW TW T + + + +
4 W TW TW TW T + +
5 W TW TW TW T + + + + +
6 W TW TW TW T + + + + +
7 WT WT WT WT +++ +++
8 W TW TW TW T + + +
9 W TW TW TW T + + + +
10 WT WT WT WT ++ +
11 WT WT WT WT ++ +
12 WT WT WT WT +++ +++
13 WT WT WT WT ++ +
14 WT WT WT WT + +
15 WT WT WT WT ++++ ++++
16 WT WT WT WT ++ +++
17 WT WT WT WT + +
18 WT WT WT WT +++ +
19 WT WT WT WT ++++ +
Positive control
cutaneous
melanoma
V599E NA NA NA +++ ++++
The level of expression of the Western blotting and immunhistochemistry (IHC) experiments were scored and categorised as either negative (–), weakly positive (+), weak–
moderately positive (++), moderately positive (+++) or strongly positive (++++). NA¼not applicable.
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sactivation in uveal melanoma, independent of RAS and BRAF
mutations, has also been reported recently by others (Rimoldi
et al, 2003; Weber et al, 2003; ), but the mechanism is unknown.
Recently, an interaction has been found between the MAPK and
the PTEN pathways, both frequently activated in parallel to
promote cutaneous melanoma development (Tsao et al, 2004). It is
tempting to speculate that MAPK activation in uveal melanoma
may arise via crosstalk with the PI3K/PTEN/AKT pathway,
possibly as a consequence of mutation of some of its components
(other than PTEN, which is not mutated in this tumour type).
Thus, mutation analysis of the PI3K and AKT gene families in
uveal melanomas seems warranted. Interestingly, Graells et al
(2004) demonstrated that the proangiogenic vascular endothelial
growth factor (VEGF), which is frequently highly expressed in
Table 3 Summary of published RAS and BRAF mutation studies in ocular melanoma
Study Sample type
BRAF mutation
frequency
NRAS mutation
frequency
KRAS mutation
frequency
HRAS mutation
frequency
Activation of other
MAPK members
Mooy et al (1991) 11 tumours — Codons 12,13,61 (0/
29)
—— —
Soparker et al
(1993)
11 tumours — Exon 1 (0/33) Exon 1 (0/36) 0/23 —
Exon 2 (0/39)
Edmunds et al
(2003)
11 tumours 0/48 — — — —
Cohen et al (2003) 11 tumours 0/29 — — — —
Rimoldi et al (2003) 11 tumours 0/10 — — — Expression of MEK/ERK
21 tumours 0/30
Weber et al (2003) 11 tumours 0/42 0/42 0/42 — Phospho-ERK (36/42)
baseline expression
ERK (42/42)
21 tumours 0/3 0/3 0/3
Cruz et al (Cancer
Res.)
Tumours
a 0/62 Exon 1 (0/22) — — —
Exon 2 (0/47)
Calipel et al (2003) Cell lines 3/3
b — — — High MEK/ERK levels
Kilic et al (2004) 11 tumours 0/33 — — — —
Cell lines 1/11
This study 11 tumours 0/19 0/19 0/19 0/19 Activation MAPK
pathway: MEK, ELK,
ERK
Cell lines 1/10 0/10 0/10 0/10
aNot specified if samples were from primary or secondary tumours.
bAll V599E.
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Figure 1 Expression levels of members of the MAPK pathway downstream of RAS and BRAF in 11 uveal melanoma cell lines. Actin levels were assessed
as a loading control.
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Figure 2 ERK1/2 and phospho-ERK1/2 expression in uveal melanoma
cell lines (Mel 202, Ocm 1, Mel 285, Mel 290) cultured with (þ) and
without ( ) serum (24h). A similar lack of effect of serum on influencing
the level of phospho-ERK1/2 was seen for each of the other uveal
melanoma cell lines (data not shown).
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suveal melanoma (Stitt et al, 1998; Sheidow et al, 2000), could
operate in cutaneous melanoma as a survival factor through
increasing MAPK and PI3K pathway activity. It is possible that
MAPK activation is such a crucial requirement for uveal melanoma
development because it similarly provides survival, and/or
antiapoptotic signals, necessary for tumour cell growth and
maintenance.
Although many uveal melanoma samples have been studied for
BRAF and NRAS mutations, few have been analysed for MAPK
activation and there is the implicit assumption that this pathway is
not involved in uveal melanoma genesis. Our study is the only
study design providing mutation information on all RAS members
and expression data on a wide range of participants in the MAPK
pathway. Our data thus support the notion that activation of
MAPK is indeed involved in the development of uveal melanoma,
but occurs via a different mechanism(s) to that in the majority of
cutaneous melanomas. This conclusion has significant ramifica-
tions for the development of rational therapies to treat uveal
melanoma as it implies that general inhibitors of the pathway may
still be effective even though the tumours do not have mutations of
RAS or BRAF.
ACKNOWLEDGEMENTS
We thank Dr AD Singh for generously providing a panel of fresh
frozen primary uveal melanoma specimens, Dr M Bernsen and P
Rombout for the cutaneaous melanoma sections (Department of
Pathology, University Medical Centre Nijmegen) and Drs Ksander
and Kan-Mitchell for providing some of the cell lines. This work
was supported by the National Health and Medical Research
Council of Australia, the ‘Rotterdamse Vereniging Blindenbelan-
gen’ and the ‘Landelijke Stichting voor Blinden en Slechtzienden’.
FvN is supported by the Netherlands Organisation for Scientific
Research and by the Dutch Cancer Society. NG is a recipient of an
Aspasia fellowship of the Netherlands Organisation for Scientific
Research.
REFERENCES
Alsina J, Gorsk DH, Germino FJ, Shih W, Lu SE, Zhang ZG, Yang JM, Hait
WN, Goydos JS (2003) Detection of mutations in the mitogen-activated
protein kinase pathway in human melanoma. Clin Cancer Res 9: 6419–6425
Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E,
Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C,
Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL
(2002) BRAF and RAS mutations in human lung cancer and melanoma.
Cancer Res 62: 6997–7000
Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychene A, Mascarelli F
(2003) Mutation of B-Raf in human choroidal melanoma cells mediates
cell proliferation and transformation through the MEK/ERK pathway. J
Biol Chem 278: 42409–42418, doi:10.1074/jbcM308709200
Cohen Y, Goldenberg-Cohen N, Parrella P, Chowers I, Merbs SL, Pe’er J,
Sidransky D (2003) Lack of BRAF mutation in primary uveal melanoma.
Invest Ophthalmol Vis Sci 44: 2876–2878, doi:10.1167/iovs.02-1329
C o h e nY ,R o s e n b a u mE ,B e g u mS ,G o l d e n b e r gD ,E s c h eC ,L a v i eO ,S i d r a n s k y
D, Westra WH (2004) Exon 15 BRAF mutations are uncommon in
melanomas arising in nonsun-exposed sites. Clin Cancer Res 10: 3444–3447
Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, Cotsonis G,
Cerimele F, Govindarajan B, Macaron N, Arbister JL (2002) Mitogen-
activated protein kinase activation is an early event in melanoma
progression. Clin Cancer Res 8: 3728–3733
Cruz III F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge
T, Heinrich MC, Corless CL (2003) Absence of BRAF and NRAS
mutations in uveal melanoma. Cancer Res 63(18): 5761–5766
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J,
Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R,
Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A,
Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H,
Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K,
Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G,
Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber
BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster
R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human
cancer. Nature 417: 949–954, doi:10.1038/nature00766
de Waard-Siebinga I, Blom DJ, Griffioen M, Schrier PI, Hoogendoorn E,
Beverstock G, Danen EH, Jager MJ (1995) Establishment and character-
ization of an uveal-melanoma cell line. Int J Cancer 62: 155–161
Diener-West M, Hawkins BS, Markowitz JA, Schachat AP (1992) A review
of mortality from choroidal melanoma. II. A meta-analysis of 5-year
mortality rates following enucleation, 1966 through 1988. Arch
Ophthalmol 110: 245–250
Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaronson SA (2003)
BRAF oncogenic mutations correlate with progression rather than
initiation of human melanoma. Cancer Res 63(14): 3883–3885
Edmunds SC, Cree IA, Di Nicolantonio F, Hungerford JL, Hurren JS, Kelsell
DP (2003) Absence of BRAF gene mutations in uveal melanomas in
contrast to cutaneous melanomas. Br J Cancer 88: 1403–1405,
doi:10.1038/sj.bjc.6600919
Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, Houghton AN,
Busam K, Polsky D (2003) Analysis of BRAF and N-RAS mutations in
metastatic melanoma tissues. Cancer Res 63(14): 3955–3957
Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J, Gonzalez
FJ, Fabra A (2004) Overproduction of VEGF concomitantly expressed
with its receptors promotes growth and survival of melanoma cells
through MAPK and PI3K signaling. J Invest Dermatol 123: 1151–1161
Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J
(1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a
frequent event in malignant melanoma. Cancer Res 57: 3660–3663
Kan-Mitchell J, Mitchell MS, Rao N, Liggett PE (1989) Characterization of
uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest
Ophthalmol Vis Sci 30: 829–834
Kilic E, Bruggenwirth HT, Verbiest MM, Zwarthoff EC, Mooy NM, Luyten
GP, De Klein A (2004) The RAS-BRAF kinase pathway is not involved in
uveal melanoma. Melanoma Res 14: 203–205
Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen
S, Hemminki K (2003a) BRAF mutations in metastatic melanoma: a
possible association with clinical outcome. Clin Cancer Res 9: 3362–3368
Kumar R, Angelini S, Hemminki K (2003b) Activating BRAF and N-Ras
mutations in sporadic primary melanomas: an inverse association with
allelic loss on chromosome 9. Oncogene 22: 9217–9224, doi:10.1038/
sj.onc.1206909
Luyten GP, Naus NC, Mooy CM, Hagemeijer A, Kan-Mitchell J, van Drunen
E, Vuzevski V, de Jong PT, Luider TM (1996) Establishment and
characterization of primary and metastatic uveal melanoma cell lines. Int
J Cancer 66: 380–387, doi:10.1002/(sici)1097-0215
Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, Ono T,
Albertson DG, Pinkel D, Bastian BC (2003) Determinants of BRAF
mutations in primary melanomas. J Natl Cancer Inst 95: 1878–1890
Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for
extracting DNA from human nucleated cells. Nucl Acids Res 16: 1215
Mooy CM, de Jong PT (1996) Prognostic parameters in uveal melanoma: a
review. Surv Ophthalmol 41: 215–228
Mooy CM, Van der Helm MJ, Van der Kwast TH, De Jong PT, Ruiter DJ,
Zwarthoff EC (1991) No N-ras mutations in human uveal melanoma: the
role of ultraviolet light revisited. Br J Cancer 64: 411–413
Naus NC, Zuidervaart W, Rayman N, Slater R, van Drunen E, Ksander B,
Luyten GP, Klein A (2000) Mutation analysis of the PTEN gene in uveal
melanoma cell lines. Int J Cancer 87: 151–153
Omholt K, Platz A, Kanter L, Ringborg U, Hansson J (2003) NRAS and
BRAF mutations arise early during melanoma pathogenesis and are
preserved throughout tumor progression. Clin Cancer Res 9: 6483–6488
Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses
TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray
MAPK pathway activation in uveal melanoma
W Zuidervaart et al
2037
British Journal of Cancer (2005) 92(11), 2032–2038 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sP, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS (2003) High frequency
of BRAF mutations in nevi. Nat Genet 33: 19–20, doi:10.1038/ng1054
Reifenberger J, Knobbe CB, Sterzinger AA, Blaschke B, Schulte KW,
Ruzicka T, Reifenberger G (2004) Frequent alterations of Ras signaling
pathway genes in sporadic malignant melanomas. Int J Cancer 109:
377–384, doi:10.1002/ijc.11722
Rimoldi D, Salvi S, Lienard D, Lejeune FJ, Speiser D, Zografos L, Cerottini
JC (2003) Lack of BRAF mutations in uveal melanoma. Cancer Res 63:
5712–5715
Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle
P, Elder DE, Herlyn M (2003) Constitutive mitogen-activated protein
kinase activation in melanoma is mediated by both BRAF mutations and
autocrine growth factor stimulation. Cancer Res 63: 756–759
S c o t tR J ,V a j d i cC M ,A r m s t r o n gB K ,A i n s w o r t hC J ,M e l d r u mC J ,A i t k e nJ F ,
Kricker A (2002) BRCA2 mutations in a population-based series of patients
with ocular melanoma. Int J Cancer 102: 188–191, doi:10.1002/ijc.10693
Sheidow TG, Hooper PL, Crukley C, Young J, Heathcote JG (2000)
Expression of vascular endothelial growth factor in uveal melanoma and
its correlation with metastasis. Br J Ophthalmol 84: 750–756
Shinozaki M, Fujimoto A, Morton DL, Hoon DS (2004) Incidence of BRAF
oncogene mutation and clinical relevance for primary cutaneous
melanomas. Clin Cancer Res 10: 1753–1757
Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM,
Potter AM, Rees RC (1997) Abnormalities of chromosomes 3 and 8 in
posterior uveal melanoma correlate with prognosis. Genes Chromosomes
Cancer 19: 22–28, doi:10.1002/(sici)1098-2264(199705)
Soparker CN, O’Brien JM, Albert DM (1993) Investigation of the role of the
ras protooncogene point mutation in human uveal melanomas. Invest
Ophthalmol Vis Sci 34: 2203–2209
Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP
(2003) Loss of PTEN promotes tumor development in malignant
melanoma. Cancer Res 63: 2881–2890
Stitt AW, Simpson DA, Boocock C, Gardiner TA, Murphy GM, Archer DB
(1998) Expression of vascular endothelial growth factor (VEGF) and its
receptors is regulated in eyes with intra-ocular tumours. J Pathol 186:
306–312
Tsao H, Goel V, Wu H, Yang G, Haluska FG (2004) Genetic interaction
between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in
melanoma. J Invest Dermatol 122: 337–341
Uribe P, Wistuba II, Gonzalez S (2003) BRAF mutation: a frequent event in
benign, atypical, and malignant melanocytic lesions of the skin. Am J
Dermatopathol 25: 365–370
van der Velden PA, Metzelaar-Blok JA, Bergman W, Hurks HMH, Frants
RR, Gruis NA, Jager MJ (2001) Promoter hypermethylation: a common
cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res
61: 5303–5306
van Elsas A, Zerp SF, van der Flier S, Kruse KM, Aarnoudse C, Hayward
NK, Ruiter DJ, Schrier PI (1996) Relevance of ultraviolet-induced N-ras
oncogene point mutations in development of primary human cutaneous
melanoma. Am J Pathol 149: 883–893
Weber A, Hengge UR, Urbanik D, Markwart A, Mirmohammadsaegh,
Reichel MB, Wittekind C, Wiedemann P, Tannapfel A (2003) Absence of
mutations of the BRAF gene and constitutive activation of extracellulr-
regulated kinase in malignant melanomas of the uvea. Lab Invest 83:
1771–1776, doi:10.1097/01.LAB.0000101732.89463.29
Yazdi AS, Palmedo G, Flaig MJ, Kutzner H, Sander CA (2003) SP-11
different frequencies of a BRAF point mutation in melanocytic skin
lesions. Pigment Cell Res 16: 580
MAPK pathway activation in uveal melanoma
W Zuidervaart et al
2038
British Journal of Cancer (2005) 92(11), 2032–2038 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s